Learn About Your Genetics

A Single Nucleotide Polymorphism, or SNP (pronounced "snip"), is a variation at a single position in your DNA sequence. Think of your genome as a 3-billion-letter book — a SNP is where one letter differs between people (International Human Genome Sequencing Consortium, 2001). For example, at a specific position, some people might have the letter 'A' while others have a 'G'.

SNPs are the most common type of genetic variation. There are roughly 4-5 million SNPs in each person's genome, and over 600 million known SNPs catalogued in the dbSNP database (Sherry et al., 2001). Most SNPs have no observable effect, but some can influence how you respond to medications, your risk for certain diseases, or visible traits like hair color (Bush & Moore, 2012).

When we analyze your genome data, we're looking at specific SNPs that scientific studies called Genome-Wide Association Studies (GWAS) have linked to health conditions, drug metabolism, or other traits (Visscher et al., 2017). Each SNP is identified by an 'rs number' — like rs7903146, which is associated with Type 2 diabetes risk through the TCF7L2 gene (Grant et al., 2006).

It's important to understand that having a 'risk variant' at a SNP doesn't mean you'll develop a condition. Most traits and diseases are influenced by hundreds or thousands of SNPs, plus environmental factors, lifestyle, and epigenetics (Manolio et al., 2009). A single SNP typically contributes only a small increase in statistical risk — your genetics are just one piece of a much larger puzzle.

Pharmacogenomics (PGx) is the study of how your genes affect your response to medications (Weinshilboum & Wang, 2004). It's the science behind why a standard dose of a drug might work perfectly for one person, cause side effects in another, and have no effect at all on a third. The answer often lies in genetic variations in drug-metabolizing enzymes.

The most important pharmacogenes include the CYP450 family — particularly CYP2D6, CYP2C19, CYP2C9, and CYP3A4. These liver enzymes metabolize an estimated 70-80% of all prescription drugs (Zanger & Schwab, 2013). Genetic variants in these genes can make you a 'poor metabolizer' (drug builds up, more side effects), 'normal metabolizer,' 'rapid metabolizer,' or 'ultra-rapid metabolizer' (drug is cleared too fast to be effective) (Ingelman-Sundberg et al., 2007).

Real-world examples make this tangible: the blood thinner clopidogrel (Plavix) requires CYP2C19 to convert it into its active form. Approximately 2-15% of people are poor metabolizers who achieve reduced antiplatelet effects — a potentially life-threatening gap (Mega et al., 2009). Similarly, codeine requires CYP2D6 to become morphine; ultra-rapid metabolizers can experience dangerous toxicity from standard doses, which led the FDA to add a boxed warning (FDA, 2013).

Organizations like CPIC (Clinical Pharmacogenetics Implementation Consortium) publish evidence-based guidelines for adjusting drug therapy based on genetic test results (Relling & Klein, 2011). GenomeInsight analyzes 14 key pharmacogenes against these guidelines, helping you understand how your body might process common medications. Always discuss results with your healthcare provider before making any changes to your medications.

Carrier screening tests whether you carry a gene variant for a recessive genetic condition. Being a 'carrier' means you have one working copy and one altered copy of a gene. You're typically perfectly healthy because the working copy compensates — but if both parents are carriers of the same condition, each child has a 25% chance of being affected (Kaback, 2000).

Some of the most well-known conditions screened for include Cystic Fibrosis (CF), Sickle Cell Disease, Tay-Sachs Disease, and Spinal Muscular Atrophy (SMA). Carrier frequencies vary by population — approximately 1 in 25 people of European descent carry a CF mutation (Castellani & Assael, 2017), while about 1 in 12 African Americans carry a sickle cell trait (Hassell, 2010).

Modern expanded carrier screening panels can test for over 200 conditions simultaneously using DNA from a saliva or blood sample (Haque et al., 2016). Consumer genotyping services like 23andMe test for a subset of carrier variants. GenomeInsight analyzes your raw data against known pathogenic variants to identify potential carrier status for multiple conditions.

It's crucial to understand limitations: consumer genotyping tests only look at specific known variants, not the complete gene sequence. A 'not a carrier' result doesn't guarantee you don't carry a rare or novel mutation (Henneman et al., 2016). For family planning decisions, clinical-grade carrier screening through a genetic counselor is recommended. Our results are educational and should complement, not replace, professional genetic counseling.

The APOE (Apolipoprotein E) gene comes in three common variants: ε2, ε3, and ε4. Everyone inherits two copies — one from each parent. The ε3 variant is most common (found in ~77% of the population) and is considered the 'baseline' risk (Farrer et al., 1997). The ε4 variant, carried by about 25% of people, is the strongest known common genetic risk factor for late-onset Alzheimer's disease (Corder et al., 1993).

Having one copy of APOE ε4 increases Alzheimer's risk about 3-fold, while two copies (homozygous ε4/ε4, found in ~2-3% of people) increases risk about 8-12 fold (Farrer et al., 1997). Conversely, the ε2 variant appears protective — it's associated with lower Alzheimer's risk and potentially longer lifespan (Reiman et al., 2020). The mechanism involves how efficiently different APOE variants clear amyloid-beta protein from the brain (Liu et al., 2013).

However, context is critical. APOE ε4 is a risk factor, not a diagnosis. Many ε4 carriers never develop Alzheimer's, and many Alzheimer's patients don't carry ε4. The lifetime risk of Alzheimer's for a single ε4 carrier is estimated at 20-30% (compared to ~10% for non-carriers), meaning 70-80% of single-copy carriers will NOT develop the disease (Genin et al., 2011). Lifestyle factors — exercise, cognitive engagement, cardiovascular health, sleep quality — significantly modulate this genetic risk (Livingston et al., 2020).

The decision to learn your APOE status is personal and complex. Some people find the knowledge empowering — it motivates preventive lifestyle changes. Others find it anxiety-inducing with limited actionable options currently available. Emerging therapies like lecanemab (Leqembi) are beginning to show that early intervention may slow cognitive decline (van Dyck et al., 2023). If you choose to check your APOE status through GenomeInsight, we strongly recommend discussing results with a healthcare provider or genetic counselor.

When you spit into a tube for 23andMe or swab your cheek for AncestryDNA, you're providing cells that contain your complete genome. Each cell holds about 6.4 billion base pairs of DNA packed into 23 pairs of chromosomes (International Human Genome Sequencing Consortium, 2004). The testing lab extracts this DNA from your cells, purifies it, and prepares it for genotyping.

Consumer DNA tests use a technology called SNP microarray chips — small silicon chips manufactured by Illumina that contain hundreds of thousands of tiny DNA probes (LaFramboise, 2009). Each probe is designed to detect a specific SNP. Your fragmented, labeled DNA washes over the chip and binds to matching probes. Fluorescent signals indicate which variant (allele) you have at each position. Modern chips test 600,000 to over 1 million SNPs.

The raw data file you can download contains your genotype at each tested position: the chromosome, position, rs identifier, and your two alleles (one from each parent). This is typically a text file of 10-30 MB with hundreds of thousands of rows. Formats include 23andMe's text format, AncestryDNA's text format, and the standard VCF (Variant Call Format) used in clinical genomics (Danecek et al., 2011).

GenomeInsight takes this raw data and matches your genotypes against curated databases of clinically significant variants. We don't re-sequence or re-genotype your DNA — we interpret what's already been measured. This means our analysis is only as comprehensive as the variants on the original chip. For clinical-grade analysis, whole genome sequencing (WGS) provides far more complete coverage, testing billions of positions rather than just hundreds of thousands (Schwarze et al., 2018).

The quest to understand why some people live past 100 has revealed a complex interplay of genetics and lifestyle. Twin studies suggest that genetics account for roughly 20-30% of the variation in human lifespan, with the remaining 70-80% attributable to environmental and lifestyle factors (Herskind et al., 1996). However, the genetic component becomes increasingly important at extreme ages — centenarians cluster in families more than expected by chance (Sebastiani et al., 2012).

The most replicated longevity gene is FOXO3. The rs2802292 variant in FOXO3 has been associated with exceptional longevity across multiple populations worldwide — from Japanese-Americans in Hawaii to German centenarians to Chinese nonagenarians (Willcox et al., 2008; Flachsbart et al., 2009). FOXO3 works by regulating cellular autophagy, oxidative stress resistance, and stem cell maintenance (Morris et al., 2015).

APOE is the other major player. The ε2 variant is enriched in centenarians, while ε4 is depleted (Sebastiani et al., 2012). Other genes showing associations with longevity include CETP (cholesterol metabolism — the I405V variant is linked to higher HDL and longevity; Barzilai et al., 2003), TERT (telomere maintenance), and KLOTHO (the so-called 'anti-aging gene' that influences kidney function, cognition, and calcium metabolism; Arking et al., 2002).

Perhaps the most important takeaway from longevity genetics is what it reveals about actionable pathways. The genes associated with long life point to specific biological processes: inflammation control, cellular repair, cardiovascular protection, and stress resilience. Even without favorable longevity variants, you can influence these same pathways through exercise, caloric moderation, stress management, strong social connections, and adequate sleep (Buettner & Skemp, 2016). Your genes load the gun, but your lifestyle pulls — or doesn't pull — the trigger.